Cencora Q3 Sales Surpass Estimates, Revenue Up 5.9% YoY to $83.73 Billion

Cencora, a global pharmaceutical distribution company, reported Q3 CY2025 results with sales up 5.9% YoY to $83.73 billion, beating Wall Street's revenue expectations. Non-GAAP profit of $3.84 per share was 1.4% above analysts' consensus estimates. The company's adjusted EPS guidance for FY2026 is $17.60, beating analyst estimates by 0.7%. Cencora's revenue growth over the last five years was 11.1% CAGR, slightly above the average healthcare company.